SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Jan 30, 2017 → May 6, 2019
NCT ID
NCT03053063About SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg
SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg is a phase 3 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03053063. Target conditions include Nonalcoholic Steatohepatitis.
What happened to similar drugs?
0 of 5 similar drugs in Nonalcoholic Steatohepatitis were approved
Approved (0) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03053050 | Phase 3 | Terminated |
| NCT03053063 | Phase 3 | Terminated |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis